In the development of medical devices, data privacy in clinical trials has become as essential as safety and performance.
The data collected from participants — biometric, physiological, or behavioral — form the backbone of clinical evidence, but they are also among the most sensitive personal data under European and French law.
Failure to comply with data protection rules not only exposes manufacturers to sanctions, but can also jeopardize the validity of clinical trials and even the regulatory conformity of the medical device itself.
A strict European framework for data privacy in clinical research
Since the entry into force of Regulation (EU) 2016/679 (GDPR), all processing of personal health data is subject to a high level of protection.
Clinical trials involving medical devices must therefore comply with both:
- The Medical Device Regulation (MDR – EU 2017/745), which governs device safety and performance, and
- The GDPR, which ensures lawfulness, transparency, and security of data processing.
The European Commission reminds in its official guidance that data protection and clinical trial rules “must be applied in a complementary and consistent manner.”
(European Commission – Data protection and clinical trials)
Key principles of data privacy in medical device research
1. Legal basis and informed consent
Processing of personal health data in a clinical trial must rely on a clear legal basis: informed consent from participants, or, in some cases, another lawful ground defined by the GDPR (public health interest, legal obligation, etc.).
Participants must be informed of the research purpose, data retention periods, and data recipients.
2. Data minimization and pseudonymization
Only the data strictly necessary for the study may be collected.
They must be pseudonymized to limit re-identification risks while preserving the ability to ensure clinical follow-up.
3. System security and traceability
Data generated by connected medical devices or digital applications must be protected against loss, alteration, or unauthorized access.
Security measures include encryption, controlled access, and complete traceability of all operations.
(Source: Quaregia – Data protection for medical devices)
Governance and documentation requirements
Each sponsor or manufacturer must implement a robust data governance framework, including:
- Appointment of a Data Protection Officer (DPO),
- Maintenance of a data processing register, and
- Completion of a Data Protection Impact Assessment (DPIA) whenever there is a high risk to individuals’ rights — which is almost always the case in health research.
All these elements must be documented and integrated into the technical file of the device, on the same level as other clinical and regulatory compliance evidence.
(Source: CNIL – Data authorization requests)
The specific role of the CNIL in France
In France, the CNIL (Commission Nationale de l’Informatique et des Libertés) oversees compliance of all health data processing activities, including clinical trials involving medical devices.
It has defined several reference methodologies (MR-001 to MR-006) that govern how data can be collected, stored, and secured, depending on the research type (interventional, observational, routine care, etc.).
Any clinical trial conducted in France must comply with one of these methodologies or obtain specific authorization.
(Source: CNIL – Health research reference frameworks)
Case focus: medical devices using artificial intelligence
When a medical device integrates artificial intelligence (AI), data privacy obligations intensify.
AI models often process large volumes of health data — sometimes continuously or adaptively.
In such cases, the CNIL recommends:
- Conducting a comprehensive DPIA,
- Documenting model transparency and explainability, and
- Ensuring human oversight, so automated decisions never replace clinical judgment.
These requirements anticipate the forthcoming European AI Act (Regulation EU 2024/1689), which classifies AI-enabled medical devices as “high-risk systems.”
The regulation will apply in full starting August 2027.
(Sources: CNIL – AI and personal data; AI Act – EUR-Lex official text)
Anticipating compliance from the design stage
For manufacturers and sponsors, anticipating data protection in clinical trials from the design phase provides several advantages:
- Ensures regulatory compliance with MDR and GDPR,
- Secures CE marking and technical dossier validation,
- Strengthens the credibility of clinical evidence with authorities and ethics committees.
This privacy-by-design approach is now a competitive advantage. It builds trust among participants, hospitals, and regulators while avoiding late protocol revisions that could delay market access.
(Source: Greenlight Guru – GDPR and clinical trials for medical devices)
Conclusion: data privacy as a cornerstone of ethical clinical research
Data privacy in clinical trials for medical devices is now a compliance challenge as critical as technical performance or clinical safety.
Between the MDR, GDPR, CNIL, and the upcoming AI Act, manufacturers must treat data as both a clinical and ethical asset.
Anticipating these obligations from the earliest design stages ensures a secure, compliant, and sustainable development process — serving science, patients, and long-term trust in digital health innovation.
Useful link
